A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years

Transplantation
Flavio VincentiJohn Pirsch

Abstract

The 1-year results of the Phase III U.S. Multicenter Trial comparing tacrolimus (FK506)- and cyclosporine (CsA)-based immunosuppressive therapy in kidney transplantation revealed a significant reduction in the incidence and severity of acute rejection episodes among patients maintained on tacrolimus. The present report at 5 years of follow-up focuses on the long-term impact of tacrolimus treatment on kidney allograft outcome. The study protocol permitted crossover of patients to the alternate treatment arm under stringent conditions. The effect of crossover on graft survival was analyzed. Cardiovascular risk factors and serious adverse events were also monitored over 5 years. Intent-to-treat analysis revealed equivalent patient and graft survival between treatment arms at 5 years of follow-up (79.1% vs. 81.4%; P=0.472 and 64.3% vs. 61.6%; P=0.558 among tacrolimus and CsA-treated patients, respectively). However, the rate of crossover was significantly higher among patients randomized to receive CsA-based therapy (27.5% vs. 9.3%; P<0.001). The incidence of treatment failure (43.8% vs. 56.3%; P=0.008) was significantly lower among tacrolimus-treated patients. Graft survival was significantly improved in the tacrolimus treatment a...Continue Reading

References

Oct 27, 1994·The New England Journal of Medicine·UNKNOWN U.S. Multicenter FK506 Liver Study Group
Jan 16, 1999·Baillière's Clinical Gastroenterology·K E McColl

❮ Previous
Next ❯

Citations

Oct 29, 2004·Advances in Therapy·Mustafa BalalNeslihan Seyrek
May 5, 2005·Irish Journal of Medical Science·P O'KellyP J Conlon
Nov 8, 2011·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Di JinYong Zhao
Oct 24, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Tomás Seeman
Nov 29, 2012·Current Diabetes Reports·Ashley TherasseMark E Molitch
Mar 14, 2013·Current Hypertension Reports·Heather LaGuardia, Rubin Zhang
Aug 13, 2013·Current Hypertension Reports·Beje ThomasTitte R Srinivas
Apr 28, 2005·The Journal of Surgical Research·Nicholas R BrookMichael L Nicholson
Mar 26, 2004·Transplantation Proceedings·D A HesselinkW Weimar
Mar 26, 2004·Transplantation Proceedings·A G Jardine, C C Geddes
Mar 26, 2004·Transplantation Proceedings·B D Maes, Y F Ch Vanrenterghem
Sep 10, 2003·Transplantation Proceedings·D HernándezV Torregrosa
Jul 3, 2003·Seminars in Nephrology·Arjang DjamaliJohn D Pirsch
Nov 20, 2002·Journal of the American College of Surgeons·Richard D Williams
Aug 30, 2003·Surgery·Chumpon WilasrusmeeDilip S Kittur
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Agnes Lo
Mar 3, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bernhard K KrämerUNKNOWN European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group
Feb 9, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bernhard K KrämerUNKNOWN European Tacrolimus versus Ciclosporin Microemulsion Renal Transplantation Study Group
Jan 4, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jose Maria MoralesJesus Bustamante
Jun 7, 2003·Transplantation·Sundaram Hariharan
Jun 18, 2004·Transplantation·Flavio Vincenti
Jun 18, 2004·Transplantation·Cynthia A Galbraith, Donna Hathaway
Jun 18, 2004·Transplantation·M Roy First, William E Fitzsimmons
Jun 9, 2005·Transplantation·Johannes P van HooffElly M van Duijnhoven
Sep 24, 2005·Transplantation·Robert S WoodwardDaniel C Brennan
Oct 9, 2012·Current Opinion in Nephrology and Hypertension·Robert W Steiner
Jul 16, 2008·Transplantation·Paul BolinUNKNOWN OPTIMA Study Group
Jun 16, 2010·Transplantation·Ben Sprangers, Yves Vanrenterghem

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.